Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswePS1dE9 transgenic model of Alzheimer disease: Effects of melatonin or ramelteon

Chronobiology International

Volumn 29, Issue 7, 2012, Pages 822-834

  Otalora, Beatriz Baño ^a   Popovic, Natalija ^b   Gambini, Juan ^c   Popovic, Miroljub ^b   Viña, José ^c   Bonet Costa, Vicent ^c   Reiter, Russel J ^d   Camello, Pedro Javier ^e   Rol, Maria Ángeles ^a   Madrid, Juan Antonio ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Alzheimer disease; Body temperature rhythm; Circadian system; Hippocampus; Melatonin; Oxidative stress; Ramelteon; Spatial memory

Indexed keywords

AMYLOID PRECURSOR PROTEIN; INDENE DERIVATIVE; MELATONIN; MELATONIN RECEPTOR; MUTANT PROTEIN; PRESENILIN 1; RAMELTEON;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BODY TEMPERATURE; CIRCADIAN RHYTHM; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HIPPOCAMPUS; MALE; MEMORY; METABOLISM; MOTOR ACTIVITY; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BODY TEMPERATURE; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INDENES; MALE; MELATONIN; MEMORY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTANT PROTEINS; OXIDATIVE STRESS; PRESENILIN-1; RECEPTORS, MELATONIN;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84864231259     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2012.699119     Document Type: Article

References (64)

1. Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:42-53.
2. Bliwise DL. (1994). What is sundowning? J. Am. Geriatr. Soc. 42:1009-1011.
3. Boutin JA, Audinot V, Ferry G, Delagrange P. (2005). Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sei. 26:412-419.
4. Cheng Y, Feng Z, Zhang QZ, Zhang JT. (2006). Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sin. 27:129-139.
5. desRosiers G, Hodges JR, Berrios G. (1995). The neuropsychological differentiation of patients with very mild Alzheimer's disease and/or major depression. Am. Geriatr. Soc. 43:1256-1263.
6. Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW, Bradshaw PC. (2011). Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 51:75-86.
7. Duyckaerts C, Potier MC, Delatour B. (2008). Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 115:5-38.
8. Duyckaerts C, Delatour B, Potier MC. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118:5-36.
9. Ennaceur A, Michalikova S, Bradford A, Ahmed S. (2005). Detailed analysis of the behavior of Lister and Wistar rats in anxiety, object recognition and object location tasks. Behau. Brain Res. 159:247-266.
10. Feng Z, Qin C, Chang Y, Zhang JT. (2006). Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radie. Biol. Med. 40:101-109.
11. Fisher SP, Davidson K, Kulla A, Sugden D. (2008). Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat. J. Pineal Res. 45:125-132.
12. Foster CE, Bianchet MA, Talalay P, Faig M, Amzel LM. (2000). Structures of mammalian cytosolic quinone reductases. Free Radie. Biol. Med. 29:241-245.
13. Frye CA, Waif AA. (2008). Progesterone to ovariectomized mice enhances cognitive performance in the spontaneous alternation, object recognition, but not placement, water maze, and contextual and cued conditioned fear tasks. Neurobiol. Learn. Mem. 90:171-177.
14. Furio AM, Cutrera RA, Castillo Thea V, Perez Lloret S, Riccio P, Caccuri RL, Brusco LL, Cardinali DP. (2002). Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. Cell. Mol. Neurobiol. 22:699-709.
15. Galano A, Tan DX, Reiter RJ. (2011). Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 51:1-16.
16. Garcia T, Ribes D, Colomina MT, Cabré M, Domingo JL, Gómez M. (2009). Evaluation of the protective role of melatonin on the behavioral effects of aluminum in a mouse model of Alzheimer's disease. Toxicology 265:49-55.
17. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. (2002). Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 173:183-195.
18. Gorman MR, Yellon S. (2010). Lifespan daily locomotor activity rhythms in a mouse model of amyloid-induced neuropathology. Chronobiol. Int. 27:1159-1177.
19. Gruart A, López-Ramos JC, Munoz MD, Delgado-Garcfa JM. (2008). Aged wild-type and APP, PS1, and APP+PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load. Neurobiol. Dis. 30:439-450.
20. Hardy J. (1997). Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:154-159.
21. Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, Miyamoto M. (2005). Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J. Biol. Rhythms 20:27-37.
22. Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, Gonzalez MI. (2004). Cognitive correlates of Aß deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017:130-136.
23. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younldn LH, Wagner SL, Younldn SG, Borchelt DR. (2004). Mutant presenilins specifically elevate the levels of the 42 residue ß-amyloid peptide in vivo: evidence for augmentation of a 42-specific y secretase. Hum. Mol. Genet. 13:159-170.
24. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M. (2005). Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48:301-310.
25. Lax P, Otalora BB, Esquiva G, Roi M de L, Madrid JA, Cuenca N. (2011). Circadian dysfunction in P23H rhodopsin transgenic rats: effects of exogenous melatonin. J. Pineal Res. 50:183-191.
26. Lee JH, Bliwise DL, Ansari FP, Goldstein FC, Cellar JS, Lah JJ, Levey AI. (2007). Daytime sleepiness and functional impairment in Alzheimer disease. Am. J. Geriatr. Psychiatry 15:620-626.
27. Lewy AJ, Bauer VK, Ahmed S, Thomas KH, Cutler NL, Singer CM, Moffit MT, Sack RL. (1998). The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol. Int. 15:71-83.
28. Mahlberg R, Kunz D, Sutej I, Kühl KP, Hellweg R. (2004). Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 24:456-459.
29. Marques SC, Oliveira CR, Outeiro TF, Pereira CM. (2010). Alzheimer's disease: the quest to understand complexity. J. Alzheimer Dis. 21:373-383.
30. Mathes AM, Kubulus D, Waibel L, Weiler J, Heymann P, Wolf B, Rensing H. (2008). Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit. Care Med. 36:2863-2870.
31. Merlino G, Piani A, Gigli GL, Cancelli I, Rinaldi A, Baroselli A, Serafini A, Zanchettin B, Valente M. (2010). Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: a population-based study. Sleep Med. 11:372-377.
32. Minkeviciene R, Banerjee P, Tanila H. (2004). Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. Pharmacol. Exp. Ther. 311:677-682.
33. Miyamoto M. (2006). Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci. Lett. 402:201-204.
34. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW. (2009). Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease./Pineal Res. 47:82-96.
35. Ortiz-Tudela E, Martinez-Nicolas A, Campos M, Roi MÂ, Madrid JA. (2010). A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput. Biol. 6:el000996.
36. Otâlora BB, Madrid JA, Alvarez N, Vicente V, Rol MA. (2008). Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. J. Pineal Res. 44:307-315.
37. Pappolla MA, Chyan YJ, Poeggeler B, Frangione B, Wilson G, Ghiso J, Reiter RJ. (2000). An assessment of the antioxidant and the antia-myloidogenic properties of melatonin: implications for Alzheimer's disease./Neural Transm. 107:203-231.
38. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Harde-land R. (2002). Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 33:20-30.
39. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911-1929.
40. Quinn J, Kulhanek D, Nowlin J, Jones R, Praticö D, Rokach J, Stackman R. (2005). Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 1037:209-213.
41. Redman JR, Armstrong SM. (1988). Reentrainment of rat circadian activity rhythms: effects of melatonin. J. Pineal Res. 5:203-215.
42. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. (2007). Impaired spatial learning in the APPSwe+PSENlDeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behau. 6:54-65.
43. Reiter RJ, Paredes SD, Manchester LC, Tan DX. (2009). Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol. 44:175-200.
44. Reiter RJ, Tan DX, Fuentes-Broto L. (2010). Melatonin: a multitasking molecule. Prog. Brain Res. 181:127-151.
45. Satlin A, Volicer L, Stopa EG, Harper D. (1995). Circadian locomotor activity and core-body temperature rhythms in Alzheimer's disease. Neurobiol. Aging 16:765-771.
46. Savaskan E, Olivieri G, Meier F, Brydon L, Jockers R, Ravid R Wirz-Justice A, Müller-Spahn F. (2002). Increased melatonin la-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J. Pineal Res. 32:59-62.
47. Savaskan E, Ayoub MA, Ravid R, Angeloni D, Fraschini F, Meier F, Eckert A, Müller-Spahn F, Jockers R. (2005). Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J. Pineal Res. 38:10-16.
48. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, TangF, MarkowskaAL, BorcheltDR. (2005). Episodic-like memory deficits in the APPswe/PSldE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18:602-617.
49. Scullion GA, Kendall DA, Marsden CA, Sunter D, Pardon MC. (2011). Chronic treatment with the a(2)-adrenoceptor antagonist fluparox-an prevents age-related deficits in spatial working memory in APPxPSl transgenic mice without altering ß-amyloid plaque load or astrocytosis. Neuropharmacology 60:223-234.
50. SterniczukR, DyckRH, Laferla FM, Antle MC. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Res. 1348:139-148.
51. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. (1993). Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr. J. 1:57-60.
52. Tomâs-Zapico C, Coto-Montes A. (2005). A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J. Pineal Res. 39:99-104.
53. ValentinuzziVS, Scarbrough K, Takahashi JS, TurekFW. (1997). Effects of aging on the circadian rhythm of wheel-running activity in C57BL/6 mice. Am. J. Physiol. 273:R1957-R1964.
54. van Someren EJ, Hagebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot AM, Mirmiran M, Swaab DF. (1996). Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol. Psychiatry 40:259-270.
55. Vitiello MV, Bliwise DL, Prinz PN. (1992). Sleep in Alzheimer's disease and the sundown syndrome. Neurology 42:83-93.
56. Vivanco P, Ortiz V, Rol MA, Madrid JA. (2007). Looking for the keys to diurnality downstream from the circadian clock: role of melatonin in a dual-phasing rodent, Octadon degus. J. Pineal Res. 42:280-290.
57. Vloeberghs E, Van Dam D, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP. (2004). Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur. J. Neurosci. 20:2757-2766.
58. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. (2001). Sundowning and circadian rhythms in Alzheimer's disease. Am. J. Psychiatry 158:704-711.
59. Wisor JP, Edgar DM, Yesavage J, Ryan HS, McCormick CM, Lapustea N, Murphy GM (2005). Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131:375-385.
60. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN, Sunderman FW Jr. (1987). Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin. Chem. 33:214-220.
61. Wu YH, Swaab DF. (2005). The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal Res. 38:145-152.
62. Wu YH, Swaab DF. (2007). Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 8:623-636.
63. Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. (2007). Decreased MT1 melatonin receptor expression in the suprachias-matic nucleus in aging and Alzheimer's disease. Neurobiol. Aging 28:1239-1247.
64. Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. (2004). Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 1027:59-66.